ArticleViruses2021
Characterization of a Lytic Bacteriophage against
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Antimicrobial Activity of LysX and LysP Endolysins AgainstPlants (Basel, Switzerland) · 2026Article
- Identification and analysis of the crucial holin domain and sites and the bactericidal activity of a holin-endolysin lysis cassette from phage PZL-Ah152 againstJournal of virology · 2026Article
- Characterization and genome analysis of jumbo Escherichia phage UE-S1 and the antibacterial potential of its lysozyme against uropathogenic E. coli.BMC microbiology · 2025Article
- Bacteriophages Biocontrol of Kiwifruit Bacterial Canker Caused byAntibiotics (Basel, Switzerland) · 2025Article
- Lytic properties and genomic analysis of bacteriophage Brt_Psa3, targeting Pseudomonas syringae pv. actinidiae.Applied microbiology and biotechnology · 2025Article
- Isolation and Characterization of A Novel Pbunavirus with Promising Antibiofilm Activity Against Pseudomonas Aeruginosa.Current microbiology · 2025Article
- Characterization of two novel bacteriophages (PSV6 and PSV3) as biocontrol agents againstFrontiers in microbiology · 2025Article
- Endolysins and membrane-active peptides: innovative engineering strategies against gram-negative bacteria.Frontiers in microbiology · 2025Review
- Antibacterial synergy between a phage endolysin and citric acid against the Gram-negative kiwifruit pathogenApplied and environmental microbiology · 2024Article
- Phage endolysins as new therapeutic options for multidrug resistantFrontiers in cellular and infection microbiology · 2024Article
- Article
- In planta interactions of a novel bacteriophage against Pseudomonas syringae pv. tomato.Applied microbiology and biotechnology · 2023Article
- Current trends in management of bacterial pathogens infecting plants.Antonie van Leeuwenhoek · 2023Review
- LysGR1, a novel thermostable endolysin fromFrontiers in microbiology · 2023Article
- Scientific and technological advances in the development of sustainable disease management tools: a case study on kiwifruit bacterial canker.Frontiers in plant science · 2023Review
- Biological properties of Staphylococcus virus ΦSA012 for phage therapy.Scientific reports · 2022Article
- Advancements in the Use of Bacteriophages to Combat the Kiwifruit Canker PhytopathogenViruses · 2022Review
- Characterization of Phages YuuY, KaiHaiDragon, and OneinaGillian Isolated fromInternational journal of molecular sciences · 2022Article
- A Single Catalytic Endolysin Domain Plychap001: Characterization and Application to ControlFoods (Basel, Switzerland) · 2022Article
- The Bacteriophage Pf-10-A Component of the Biopesticide "Multiphage" Used to Control Agricultural Crop Diseases Caused byViruses · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.